Retinoblastoma laboratory tests: Difference between revisions

	Retinoblastoma Microchapters
Home
Patient Information
Overview
Historical perspective
Classification
Pathophysiology
Causes
Differentiating Retinoblastoma from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural history, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
History & Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Retinoblastoma laboratory tests On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Retinoblastoma laboratory tests All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Retinoblastoma laboratory tests
CDC on Retinoblastoma laboratory tests
Retinoblastoma laboratory tests in the news
Blogs on Retinoblastoma laboratory tests
Directions to Hospitals Treating Retinoblastoma
Risk calculators and risk factors for Retinoblastoma laboratory tests

VisualWikitext

Revision as of 03:49, 14 October 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]

Overview

There are no diagnostic lab findings associated with retinoblastoma.

Laboratory Findings

There are no diagnostic lab findings associated with retinoblastoma

References

Template:WH Template:WS

Template:Nervous tissue tumors

@@ Line 1: / Line 1: @@
 __NOTOC__
 {{Retinoblastoma}}
+{{CMG}}{{AE}}{{Simrat}}
 ==Overview==
 There are no diagnostic lab findings associated with retinoblastoma.
 ==Laboratory Findings==
-'''Genetic testing:'''
+There are no diagnostic lab findings associated with retinoblastoma
-:* Bilaterally affected individuals and 13-15% of unilaterally affected individuals, are expected to show an RB1 mutation in blood. By identifying the RB1 mutation in the affected individual, (future) siblings, children, and other relatives can be tested for the mutation; if they do not carry the mutation, child relatives are not at risk of retinoblastoma so need not undergo the trauma and expense of examinations under anaesthetic. For the 85% of unilaterally affected patients found not to carry either of their eye tumor RB1 mutations in blood, neither molecular testing nor clinical surveillance of siblings is required.
-:* If the RB1 mutation of an affected individual is identified, amniotic cells in an at-risk pregnancy can be tested for the family mutation; any fetus that carries the mutation can be delivered early, allowing early treatment of any eye tumors, leading to better visual outcomes.
-:* For cases of unilateral retinoblastoma where no eye tumor is available for testing, if no RB1 mutation is detected in blood after high sensitivity molecular testing (i.e. >93% RB1 mutation detection sensitivity), the risk of a germline RB1 mutation is reduced to less than 1%, a level at which only clinic examination (and not examinations under anaesthetic) is recommended for the affected individual and their future offspring (National Retinoblastoma Strategy, Canadian Guidelines for Care).
 ==References==
 {{reflist|2}}

Retinoblastoma laboratory tests: Difference between revisions

Revision as of 03:49, 14 October 2015

Overview

Laboratory Findings

References

Navigation menu